Browse drugs

… criteria were included; of whom, 121 patients (17.4%) received edoxaban underdosing. At 12 months, the incidence of primary outcome was…

…n differences were found in patients treated with dabigatran or edoxaban.It would be advisable for regulatory agencies to issue clear re…

…ement.Results A total of 1,992 drug interactions were analysed: apixaban 531 (26.7%), dabigatran 492 (24.7%), edoxaban 411 (20.6%), riva…

…ent with national prescribing guidance (to switch patients onto edoxaban).Intervention Complex intervention including a SMOR embedded wi…

…entified, of which 149 (7.5%) involved herbal or food products: apixaban 42 (28.2%), dabigatran 42 (28.2%), edoxaban 23 (15.4%), rivarox…

…314 (28.9%), edoxaban 271 (24.9%), rivaroxaban 258 (23.7%), and apixaban 245 (22.5%). Overall agreement was low (percent agreement 49.1%…

…an or rivaroxaban) are commonly prescribed for this indication. Dabigatran, an oral direct thrombin inhibitor, is similarly approved. In v…

… LV thrombus management, with comparable efficacy and safety to warfarin. Furthermore, our findings suggest more favourable clinical out…